Background
Methods
Study population
Adrenal vein sampling
Confirmatory test
Statistical analysis
Results
Screening process of patients
Baseline characteristics of patients with AVS subtype
Variable | Lateralized N = 90 | Non-lateralized N = 51 | P value |
---|---|---|---|
Lateralization index | 12.1 ± 28.0 | 1.5 ± 0.4 | < 0.001 |
Mean Age | 49.2 ± 10.3 | 50.0 ± 10.0 | 0.88 |
Sex, M/F(n%) | 44 (48.9%)/46 (52.2%) | 22 (43.1%)/29 (56.9%) | 0.51 |
BMI (Kg/m2) | 25.9 ± 2.7 | 25.2 ± 3.7 | 0.07 |
Systolic BP (mmHg) | 145 ± 19 | 144 ± 21 | 0.32 |
Diastolic BP (mmHg) | 91 ± 13 | 90 ± 15 | 0.24 |
Serum potassium (mmol/L) | 3.6 ± 0.5 | 3.7 ± 0.5 | 0.98 |
Serum sodium (mmol/L) | 137.1 ± 21.1 | 140.1 ± 2.1 | 0.07 |
Urinary potassium (mmol/d) | 40.1 ± 15.9 | 37.8 ± 14.5 | 0.64 |
Urinary sodium (mmol/d) | 181.5 ± 108.8 | 168.8 ± 97.8 | 0.75 |
Recumbent PAC (ng/dL) | 11.9 [8.9–18.1] | 11.1 [8.4–16.5] | 0.70 |
Recumbent DRC (mU/L) | 1.6 [0.9–5.0] | 2.9 [1.3–5.6] | 0.07 |
Recumbent ARR (ng/dL)/(mU/L) | 4.8 [1.9–8.9] | 3.1 [1.7–5.9] | 0.19 |
Post-CCT/SIT ARR (ng/dL)/(mU/L) | 2.9 [1.05–6.90] | 2.2 [1.0–4.0] | 0.24 |
ACR (mg/mmol) | 118.7.1 ± 428.2 | 44.2 ± 76.5 | 0.09 |
Serum creatine (umol/L) | 68.7 ± 23.5 | 70.4 ± 48.5 | 0.24 |
eGFR (ml/min/1.73 m2) | 131.7 ± 41.0 | 137.0 ± 33.2 | 0.21 |
Hypertensive heart disease, n(%) | 6 (8.8%) | 2 (5.1%) | 0.32 |
Ischemic heart disease, n(%) | 31 (44.9%) | 13 (33.3%) | 0.71 |
Hypertensive Nephropathy,n(%) | 26 (42.6%) | 10 (27.8%) | 0.31 |
Peripheral vascular disease, n(%) | 11 (16.7%) | 2 (5.1%) | 0.19 |
Cerebrovascular disease, n(%) | 27 (50.0%) | 18 (51.4%) | 0.13 |
Metabolic syndrome, n(%) | 6 (8.8%) | 2 (5.1%) | 1.0 |
Logistic model predicting adrenal lateralization
Variable | B | SE | Wald | Pvalue | OR | 95%CI |
---|---|---|---|---|---|---|
ARR after CCT/SIT | 0.01 | 0.005 | 4.071 | 0.044 | 1.010 | 1.000 to 1.021 |
Age | N/A | N/A | N/A | 0.829 | N/A | N/A |
Serum potassium | N/A | N/A | N/A | 0.722 | N/A | N/A / |
eGFR | N/A | N/A | N/A | 0.898 | N/A | N/A |
PAC | N/A | N/A | N/A | 0.528 | N/A | N/A |
Diagnostic criteria | N | Sensitivity | Specificity |
---|---|---|---|
PAC > 171 ng/dL | 32/141 | 26.7%(17.8–37.4) | 84.3%(71.2–92.2) |
Serum potassium< 3.5 mmol/L | 54/141 | 36.7%(26.8–47.5) | 58.8%(44.2–72.4) |
Post-CCT/SIT ARR > 10(ng/dL)/(mU/L) | 15/108 | 22.1%(12.9–33.8) | 100%(93.2–100.0) |
Hypertension; Serum potassium< 3.5 mmol/L;Post-CCT/SIT ARR > 10(ng/dL)/(mU/L) | 9/108 | 13.0%(6.1–23.3) | 100%(91.0–100.0) |
Serum potassium< 3.5 mmol/L or Post-CCT/SIT ARR > 10(ng/dL)/(mU/L) | 51/108 | 49.3%(37.0–61.6) | 56.4%(39.6–72.2) |